Intellia Therapeutics Inc (NTLA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Intellia Therapeutics Inc (NTLA) Competitors
The companies most similar to Intellia Therapeutics are Beam Therapeutics (BEAM), Innoviva (INVA) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Intellia Therapeutics ranks 6th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B. The median P/E of the 3 companies with a P/E is 6.4x.
Peer Comparison
NTLA's ROIC of -50.0% is below the peer median of -29.7%, and its revenue growth of -48.0% is below the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Innoviva Inc (INVA) | $1.35B | 5.3x | 3.0x | 44.1% | 10.8% | -1.6% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Sellas Life Sciences Group Inc (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| MoonLake Immunotherapeutics (MLTX) | $1.06B | N/A | N/A | 0.0% | -54.6% | 0.0% | 0.00% |
| Jade Biosciences, Inc. (JBIO) | $1.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Precigen Inc (PGEN) | $1.63B | 98.6x | 9.9x | 15.5% | 18.9% | 2438.0% | 0.00% |
| Peer median | $1.29B | 6.4x | 16.3x | 0.0% | -29.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Intellia Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Innoviva Inc (INVA) | Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California. | INVA competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
| Sellas Life Sciences Group Inc (SLS) | SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications... | SLS competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| MoonLake Immunotherapeutics (MLTX) | MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug... | MLTX competitors |
| Jade Biosciences, Inc. (JBIO) | Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune... | JBIO competitors |
| Precigen Inc (PGEN) | Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland. | PGEN competitors |
Frequently Asked Questions About NTLA
Who are Intellia Therapeutics' main competitors?
The companies most similar to Intellia Therapeutics include Beam Therapeutics (BEAM), Innoviva (INVA), Structure Therapeutics Inc. American Depositary Shares (GPCR), Immatics NV (IMTX) and Nurix Therapeutics (NRIX), listed from the closest match.
Who is Intellia Therapeutics' biggest competitor?
Beam Therapeutics (BEAM) is both the largest of the similar companies at $2.36B and the closest match by business profile, size, sector and industry.
How does NTLA stock compare with its competitors?
NTLA's P/S is 26.1x against a peer median of 16.3x; its net margin is 0.0% against a peer median of 0.0%.
Which of Intellia Therapeutics' competitors pays a higher dividend?
Intellia Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Intellia Therapeutics bigger than its competitors?
No. Intellia Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.
NTLA pages: Overview, Earnings, Forecast, Financials, Competitors